Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HCV-art study of sofosbuvir/ledipasvir with or without ribavirin in chronic hepatitis C patients with arthritis
2016-002958-21Phase 3Terminated
- Sponsor
- Sant'Orsola-Malpighi University Hospital
- Start
- Jun 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ledipasvir and ribavirin in hepatitis C virus infection and arthritis, sponsored by Sant'Orsola-Malpighi University Hospital. Primary endpoint: Arthritis remission or improvement at end of antiviral therapy. Started Jun 2021; status: terminated.
02
Drugs
ledipasvirribavirin
03
Conditions
hepatitis C virus infectionarthritis
Beyond the preview
Go deeper on 2016-002958-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002958-21.